摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Boc-甘氨酰胺 | 35150-09-5

中文名称
Boc-甘氨酰胺
中文别名
N-叔丁氧羰基-L-甘氨酰胺
英文名称
N-(tert-butoxycarbonyl)glycine
英文别名
tert-butyl (2-amino-2-oxoethyl)carbamate;Boc-Gly-NH2;N-Boc-glycinamide;Boc-glycinamide;tert-butyl N-(carbamoylmethyl)carbamate;tert-butyl N-(2-amino-2-oxoethyl)carbamate;N-(tert-butoxycarbonyl)glycinamide;Boc-gly-OH
Boc-甘氨酰胺化学式
CAS
35150-09-5
化学式
C7H14N2O3
mdl
——
分子量
174.2
InChiKey
RHONTQZNLFIDCQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    85-87 °C
  • 沸点:
    339.7±25.0 °C(Predicted)
  • 密度:
    1.107±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -0.1
  • 重原子数:
    12
  • 可旋转键数:
    4
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.71
  • 拓扑面积:
    81.4
  • 氢给体数:
    2
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2924199090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335
  • 储存条件:
    室温且干燥环境下使用。

SDS

SDS:85b46eb10433635102177223d021ed30
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: Boc-Gly-NH2
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: Boc-Gly-NH2
CAS number: 35150-09-5

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H14N2O3
Molecular weight: 174.2

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    Boc-甘氨酰胺 氢气三乙胺三氟乙酸酐 作用下, 以 四氢呋喃乙醇 为溶剂, 50.0 ℃ 、2.07 MPa 条件下, 反应 9.0h, 生成 N-叔丁氧羰基-1,2-乙二胺
    参考文献:
    名称:
    A Convenient and General Method for the Preparation oftert-Butoxycarbonylaminoalkanenitriles and Their Conversion to Mono-tert-butoxycarbonylalkanediamines
    摘要:
    介绍了通过在三氟乙酸酐和三乙胺的存在下脱水相应的羧酰胺2(以两步法制备自氨基酸酸)合成叔丁氧羰基氨基烷腈3的新方法。N-Boc-氨基烷腈3在温和条件下很容易转化为单-N-Boc-烷二胺4,避免了N-保护基团的断裂。单保护的烷二胺4是亲和层析中有用的工具。
    DOI:
    10.1055/s-1988-27538
  • 作为产物:
    描述:
    参考文献:
    名称:
    A Convenient and General Method for the Preparation oftert-Butoxycarbonylaminoalkanenitriles and Their Conversion to Mono-tert-butoxycarbonylalkanediamines
    摘要:
    介绍了通过在三氟乙酸酐和三乙胺的存在下脱水相应的羧酰胺2(以两步法制备自氨基酸酸)合成叔丁氧羰基氨基烷腈3的新方法。N-Boc-氨基烷腈3在温和条件下很容易转化为单-N-Boc-烷二胺4,避免了N-保护基团的断裂。单保护的烷二胺4是亲和层析中有用的工具。
    DOI:
    10.1055/s-1988-27538
点击查看最新优质反应信息

文献信息

  • Primary amides as selective inhibitors of cathepsin K
    作者:Serge Léger、Christopher I. Bayly、W. Cameron Black、Sylvie Desmarais、Jean-Pierre Falgueyret、Frédéric Massé、M. David Percival、Jean-François Truchon
    DOI:10.1016/j.bmcl.2007.05.024
    日期:2007.8
    The nitrile warhead used in a series of cathepsin K inhibitors can be replaced by a less electrophilic primary amide. The accompanying loss of potency can be partially recovered by introducing a substituent alpha to the amide. The potency gain resulting from this addition is not achieved with the nitrile derivatives due to a different geometry of the cysteine adduct in the enzyme active site. This
    一系列组织蛋白酶K抑制剂中使用的腈弹头可以用亲电性较低的伯酰胺代替。通过将取代基α引入酰胺中,可以部分地弥补伴随的效力损失。由于腈活性衍生物在酶活性位点中半胱酸加合物的几何形状不同,因此用腈衍生物不能实现这种添加所带来的效价提高。这项研究导致鉴定了作为抑制底物的伯酰胺2g,对组织蛋白酶K的IC(50)为10 nM,与其他组织蛋白酶相比具有出色的选择性。
  • PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
    申请人:ANDERSON MARK B.
    公开号:US20100068197A1
    公开(公告)日:2010-03-18
    Disclosed are compounds of Formula I effective as cytotoxic agents. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    揭示的是作为细胞毒性剂有效的I式化合物。本发明的化合物在治疗多种临床病况中是有用的,这些病况中发生异常细胞的不受控制的生长和扩散。
  • [EN] HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET LEUR UTILISATION DANS LA PRÉVENTION OU LE TRAITEMENT D'INFECTIONS BACTÉRIENNES
    申请人:MUTABILIS
    公开号:WO2018060481A1
    公开(公告)日:2018-04-05
    The invention relates to a compound of formula (I) and a racemate, an enantiomer, a diastereoisomer, a geometric isomer or a pharmaceutically acceptable salt thereof, and its use as antibacterial agent.
    这项发明涉及一种式(I)的化合物及其外消旋体、对映体、二对映异构体、几何异构体或药学上可接受的盐,并且其作为抗菌剂的用途。
  • [EN] COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS ET LEURS UTILISATIONS
    申请人:FOGHORN THERAPEUTICS INC
    公开号:WO2020160100A1
    公开(公告)日:2020-08-06
    The present disclosure features compounds useful for the treatment of BAF complex-related disorders.
    本公开涉及用于治疗BAF复合物相关疾病的化合物。
  • [EN] COMPOSITION FOR THE TREATMENT OF IGF-1R EXPRESSING CANCER<br/>[FR] COMPOSITION POUR LE TRAITEMENT D'UN CANCER EXPRIMANT IGF-1R
    申请人:PF MEDICAMENT
    公开号:WO2017072196A1
    公开(公告)日:2017-05-04
    The present invention relates to a method for the treatment of IGF-IR expressing cancers as well as to a compositions and a kit for said traitment. From one aspect, the invention reates to the combined use of a first antibody for the determination of the IGF-IR status of a cancer and a second antibody used as an ADC for the treatment of said cancer.
    本发明涉及一种用于治疗表达IGF-IR的癌症的方法,以及用于所述治疗的组合物和试剂盒。从一方面来说,发明涉及第一抗体用于确定癌症的IGF-IR状态和第二抗体作为ADC用于治疗所述癌症的联合使用。
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[[[(1R,2R)-2-[[[3,5-双(叔丁基)-2-羟基苯基]亚甲基]氨基]环己基]硫脲基]-N-苄基-N,3,3-三甲基丁酰胺 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,4R)-Boc-4-环己基-吡咯烷-2-羧酸 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-N,3,3-三甲基-N-(苯甲基)丁酰胺 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S)-2-氨基-3,3-二甲基-N-2-吡啶基丁酰胺 (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,5R,6R)-5-(1-乙基丙氧基)-7-氧杂双环[4.1.0]庚-3-烯-3-羧酸乙基酯 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素(1-6) 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸